Associate Professor, Medicine, University of Colorado School of Medicine
Hematology
Dr. Thomas W. Flaig, MD
|
|
Give Review
Thomas Flaig works in the field of Hematology. He went to University of Minnesota Medical School. University of Minnesota Medical School is ranked 40 in research and 10 in primary care medicine He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Thomas Flaig is a published doctor. He published 53 publications, including: 'Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.' He accepts Medicare.
Publications
- Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate Cancer: results from PREVAIL.
- Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
- Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate Cancer.
- Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell Carcinoma.
- Geriatric Oncology for the 21st Century: A Call for Action.
- The prognostic significance of Gleason scores in metastatic prostate Cancer.
- Sequencing medical therapy in prostate Cancer: not as easy as 1-2-3.
- Collision renal cell papillary and medullary Carcinoma in a 66-year-old man.
- Targeted therapy in advanced urothelial Carcinoma.
- Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma.
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung Cancer.
- Abiraterone in metastatic prostate Cancer without previous chemotherapy.
- Clinical opportunities and challenges in targeting tumour dormancy.
- Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder Cancer.
- miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2.
- Local control rates of metastatic renal cell Carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
- Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).
- Geriatric considerations in the treatment of advanced prostate Cancer.
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell Carcinoma: a phase 1/2 study.
- Simultaneous Activation of Kras and Inactivation of p53 Induces Soft Tissue Sarcoma and Bladder Urothelial Hyperplasia.
- Bladder Cancer in 2011: The dawn of personalized medicine.
- A rare case of metastatic Renal epithelioid angiomyolipoma.
- Detection of circulating tumor cells in metastatic and clinically localized urothelial Carcinoma.
- Abiraterone and increased survival in metastatic prostate Cancer.
- Pazopanib synergizes with docetaxel in the treatment of bladder Cancer cells.
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
- Stereotactic body radiation therapy for melanoma and renal cell Carcinoma: impact of single fraction equivalent dose on local control.
- A renaissance in the medical treatment of advanced prostate Cancer.
- Adjuvant medical therapy for prostate Cancer.
- Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell Carcinoma after failure of sunitinib or sorafenib.
- VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder Cancer cells.
- Novel targeted agents for the treatment of bladder Cancer: translating laboratory advances into clinical application.
- A young woman with multiple Kidney lesions.
- A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate Cancer.
- Recurrent urothelial Carcinoma with pulmonary metastasis.
- Silibinin suppresses CD44 expression in prostate Cancer cells.
- A man with changes in the urinary Bladder: benign metaplasia or adenocarcinoma?
- Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder Cancer cells to cisplatin in a dose...
- Management of the side effects of androgen deprivation therapy in men with prostate Cancer.
- Bicalutamide-associated fulminant hepatotoxicity.
- Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell Carcinoma.
- High incidence of lung Cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials.
- Randomization reveals unexpected Acute leukemias in Southwest Oncology Group prostate cancer trial.
- Sarcoidosis in a man with Renal carcinoid tumor.
- Prostate Cancer in a man with multiple previous Cancers.
- Conference report and review: current status of biomarkers potentially associated with prostate Cancer outcomes.
- Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate Cancer cells.
- The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder Cancer cell lines.
- A phase I and pharmacokinetic study of silybin-phytosome in prostate Cancer patients.
- Mitoxantrone-associated Acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.
- A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate Cancer.
- Bone marrow transplantation for nonMalignant diseases.
Schools
University Of Minnesota Medical School
Hennepin County Medical Center Program
University Of Colorado University Hospital Program
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield PPO
- Assurant Health
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Coventry Health Care
- First Choice Health
- First Health (Coventry Health Care) PPO
- Humana
- MedHealthInsurance
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
Hennepin County Medical Center -
University of Minnesota Medical School
Hospital
-
University of Colorado Hospital
Drug Facts
| NPI NUMBER | 1881620326 | |
| NPPES Provider LastName | FLAIG | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 800452545 | |
| NPPES Provider State | CO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 355.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 40.0 | |
| Percent Opioid Claims | 11.27 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881620326 |
| Last Name Of The Provider | FLAIG |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
Dr. Benjamin Y. Scheier, MD |
|
Dr. Paul A. Bunn Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles M. Nieto, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sally P. Stabler, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Elaine T. Lam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine E. Klein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. S Gail G. Eckhardt, MD |
|
Dr. John Burke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ana B. Oton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amelia C. Ashmann, MD |
|
|
Dr. Angela M. Davies, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|